ISR identifies and explores the patterns and preferences surrounding the needs, treatments, and side-effects of patients living with autoimmune diseases. This report offers pharmaceutical, biotech, and service provider companies with an opportunity to position their product, enhance clinical development, and improve clinical trial patient recruitment. The report provides value to both commercial and clinical development decision-makers. The following autoimmune diseases are included: Celiac disease Fibromyalgia Graves’ disease Hashimoto’s disease Lupus Multiple sclerosis Rheumatoid arthritis Ulcerative colitis

1. EW
PR
EV
I
Autoimmune Diseases:
Current Treatments,
Unmet Needs, and Patient
Recruitment
Info@ISRreports.com
©2013 Industry Standard Research
www.ISRreports.com

2. act with confidence
Report Overview
ISR identifies and explores the patterns and preferences surrounding the needs, treatments, and
side-effects of patients living with autoimmune diseases. This report offers pharmaceutical, biotech,
and service provider companies with an opportunity to position their product, enhance clinical
development, and improve clinical trial patient recruitment. The report provides value to both
commercial and clinical development decision-makers.
The following autoimmune diseases are included:
• Celiac disease
• Fibromyalgia
• Graves’ disease
• Hashimoto’s disease
208
U.S.-based Respondents
•
•
•
•
181
Charts and Graphs
Lupus
Multiple sclerosis
Rheumatoid arthritis
Ulcerative colitis
118 Q4, 2013
Pages
Publication Date
Methodologies:
208 patients in the United States with an autoimmune disease completed a 20-minute web-based
quantitative survey conducted by ISR.
Major Sections:
1. Executive Summary
2. Unmet Needs of Autoimmune Patients
3. Current Abilities of Patients with Autoimmune Diseases
4. Trends in Autoimmune Diagnosis
5. Patient Care and Physician Interaction
6. Treatment Profiles and Satisfaction
Valuable For:
•
•
•
•
•
•
Medical
Marketing and Advertising
Sales
Patient Recruitment
Clinical Development
Brand Management
Learn how you can use this report.
www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
2

3. act with confidence
What you will learn in this report:
•
Prevalence of symptoms associated with each disease and the symptoms that cause
the most difficulty
•
Patient satisfaction with current abilities, the occurrence of pain, and how the disease
affects everyday life
•
How a patient’s socio-economic status and level of satisfaction with their condition/
treatment regimen affect their willingness to enroll in a clinical trial
•
Trends in disease diagnosis
•
Payment issues with insurance
•
Patient interactions with physicians (PCPs andSpecialists) and the non-medical
individuals they turn to the most for support
•
And more…
How you can use this report:
•
Design your marketing and advertising plans to account for the current issues and
unmet patient needs
•
Understand patient willingness and hesitations around enrolling in a clinical trial to
position enrollment in a positive way
•
Consider symptom relief, medication side effects, cost, and many other factors when
planning for research and development
Up next: Full table of contents and sample pages
www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
3

4. act with confidence
Table of Contents
Full Table of Contents and additional sample pages are available in the full
report, which can be downloaded here: http://www.isrreports.com/reportpreview/?report_id=2535&report_name=Autoimmune+Diseases%3A+Curr
ent+Treatments%2C+Unmet+Needs%2C+and+Patient+Recruitment
www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
4

5. act with confidence
Sample Page: Report Introduction
Introduction
act with confidence
Introduction
One
Factsway to think about the Russian clinical trial and pharmaceutical environment is
to think of the country as a publically traded pharmaceutical company� If you were
•
Autoimmune prospectus brought on by both natural and hereditary a comleafing through a diseases areor an investor presentation, you would findfactors that
cause strong macro fundamentals, historic growth, inconsistent - leading to the
pany with the autoimmune system to attack healthy cells in the bodyperformance,
and malfunction of normal bodily systems. Russia has many of the same charactersome regulatory uncertainty� In short,
•
Autoimmune diseases affect 50 million Americans.
istics as a mid-stage pharmaceutical company� And, if you take a portfolio theory
•
There are over 100 different autoimmune diseases with many more that assets
approach to investing, you would likely want to invest some portion of your remain
unidentified.
in Russia� Why?
•
Autoimmune diseases (as a category) are the leading cause of morbidity for women
↑ in the United States.
Macroeconomics: Russia is the world’s 10th largest economy
•
Women make up about 75% of all autoimmune disease diagnoses.
↑ International recognition: Joined the World Trade Organization (WTO) in 2012
Hypothesis balance sheet: Russia has ~$240B trade surplus from fossil fuel reserves
↑ Positive
• ↑ Amongst patients with an$3�9B plan aimed at having 90% consistent patterns
Focus: Putin announced autoimmune disease, there are of medicines to be
of unmet needs that 2020
locally produced by correlate to patients’ social status, family history, diagnosis
pathway, and treatment experience.
↑ Reimbursement structure: Medicines Insurance System (Aug 2012) is to be in
place
Impact by 2020 that will include a tiered rate of reimbursement, depending on
the nature of the illness, and improve access to medications
•
If the hypothesis holds, pharmaceutical companies will have an opportunity to
↑ Growth: Russian pharmaceutical market has been growing 17% annually since
frame their sales, marketing, and advertising plans to address the unmet needs of
2005
patients with an autoimmune disease. There are over $100 billion in healthcare
↑ costs associated with autoimmune are treatment naïve, offering opportunities
Untapped potential: Many patients diseases. With data regarding what autoimmune
patients want based onrecruitment
for clinical trial patient what they have experienced or currently experience,
pharmaceutical companies will be able to make more informed decisions about
↓ Uncertainty: Regulatory environment and customs practices are unstable and
how to behave in this $100 billion industry.
unpredictable
•
Since completely ridding a patient of an autoimmune disease is not only difficult,
but oftenIn 2012 the Worldthe current state of medicine,their list of economies for
↓ Difficult: impossible given Bank ranked Russia 122nd on patients express a need
more effective treatment of their persistentChina
by ease of doing business, 21 spots below conditions. But what about the current
treatments do patients want improved? Some patients may be primarily concerned
↓ Skills: Finding highly qualified healthcare professionals can be difficult
with reducing the side effects while another group of patients may be concerned
↓ with lowering the cost of is concerning
Protection: IP protection their current treatment regimen. Should this be the case,
perhaps patients with one particular autoimmune disease are interested in lower
costs, while another group of patients with another autoimmune disease seek a
relief of symptoms.
•
So while it is obvious patients want improved treatment, it is to the benefit of
pharmaceutical companies to know what particular groups of patients want in
particular areas of treatment.
•
It may be the case that patients with an autoimmune disorder who see a
neurologist as their primary physician are more interested than patients seeing a
rheumatologist in signing up for a clinical trial. This type of information leads to
money well spent by pharmaceutical companies and those involved in the clinical
development process.
www.ISRreports.com ©2013 | Russia: Clinical Development Country Profile
7
www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
5

6. act with confidence
Sample Page
2%
6%
10%
17%
8%
Cure fatigue
Find a cure/better cure
None
Other
Don't know
Current abilities of respondents with an autoimmune disease
1%
0%
2%
4%
4%
6%
11%
6%
3%
9%
7%
14%
11%
11%
19%
7%
10%
14%
34%
J,K
3%
act with confidence
Current abilities of respondents with an autoimmune
disease
General health status
General health status is:” (Base=208)
“In general, would you say your health
“In general, would you say your health is:” (Base=208)
Excellent
Very good
Good
Fair
Poor
Excellent, 3%
Poor, 8%
Very good, 11%
©Industry Standard
Research
Fair, 37%
Good, 41%
Segment differences
Segment differences
Respondents with celiac disease (29%) are more likely than respondents with
Respondents with celiac disease (29%) are more likely than respondents with fibromyalgia (8%)
fibromyalgia (8%) or rheumatoid their health to say good”�
or rheumatoid arthritis (8%) to sayarthritis (8%) is “verytheir health is “very good”.
CONDITION
Excellent
Very Good
Good
Excellent
Very Good
Good
Fair
Poor
Total
Total
(N=190)
(N=190)
3%
11%
41%
3%
11%
Condition
Celiac
Disease
Fibromyalgia
MS
Fibromyalgia
Celiac Disease (N=85)
(N=21)
(N=27)
A
B
(N=85) C
(N=21)
10%
0%
4%
B
A
29%
B,D
8%
15%
29%
10%
41%
26%
0%
29% B,D
8%
RA
RA
MS (N=74)
(N=74)
(N=27) D
3%
D
C 8%
4% 45%
3%
15%
8%
41%
29%
41%
26%
www.isrreports.com
© 2013|
R eport
T itle
g oes
h ere.
U se
t he
r uler
h andles
t o
a lign52
37%
29%
40%
48%
8%
5%
11%
7%
45%
34%
11%
©Industry Standard Research
www.ISRreports.com ©2013 | Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
51
www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com).
6

7. act with confidence
Sample Page
Full Table of Contents and additional sample pages are available in the full
report, which can be downloaded here: http://www.isrreports.com/reportpreview/?report_id=2535&report_name=Autoimmune+Diseases%3A+Curr
ent+Treatments%2C+Unmet+Needs%2C+and+Patient+Recruitment
www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
7

8. act with confidence
Ordering Information
For pricing and ordering information, please visit our website: http://
www.isrreports.com/report-preview/?report_id=2535&report_name=Auto
immune+Diseases%3A+Current+Treatments%2C+Unmet+Needs%2C+and
+Patient+Recruitment
About Industry Standard Research
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma
and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit
our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
8

9. The ISR Difference
act with confidence
Custom-quality syndicated market research
www.ISRreports.com
ISR's Reports
vs.
The Common
Syndicated Report
How confident are you?
Research methods
Mostly primary
research;
always appropriate
for the topic
vs.
vs.
One size fits all;
usually publically
available data
Data Collection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection
vs.
Struggle to recruit the right
targets and enough of them
Respondents
Sophisticated screening
ensures genuine
decision-makers
vs.
Undisclosed
methodologies and
respondent demographics
Sample Sizes
Robust sample sizes that
instill confidence
vs.
Often insufficient industry
representation that leaves you
defending results
Analysts
Decades of experience
means more insights that are
immediately usable
vs.
vs.
Junior analysts capable of
reporting numbers
www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions
10